Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express Platform

 Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express Platform

Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express Platform

Shots:

  • Merck to get rights for Cyclica’s cloud-based in-silico proteome screening AI platform, Ligand Express to screen small molecule for determining polypharmacological profiles
  • The focus of agreement is to discover and develop clinical candidates using AI and computational biophysics
  • Ligand Express Platform is an AI based platform, used for understanding drug’s effect with captured panoramic view of protein and small molecule in form of on-targets and off-targets

Click here to read full press release/ article | Ref: Merck| Image: Spagnola & Associates

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post